Capsugel has announced that Bend Research, which Capsugel acquired in September 2013, has manufactured Phase 2 clinical trial supplies of a DPI formulation, its first inhalation product manufactured at that scale. The biopharmaceutical formulation was produced at the company’s clinical trial manufacturing facility in Bend, Oregon. In late 2013, Bend Research announced that it was spending over $20 million to expand its commercial manufacturing capabilities.
Capsugel Dosage Form Solutions Head of Biotherapeutic Formulation and Processing David Lyon commented, “While drug delivery via the lung traditionally has been limited to the local treatment of respiratory diseases, there is growing interest in using these technologies for systemic delivery across a wider range of therapeutic areas, such as infectious disease and genetic disorders. For 15 years, we have worked at various stages of inhalation therapy development. By advancing our offering to include specialized DPI capsules and now clinical manufacturing supplies for biotherapeutic compounds, we are bolstering our ability to help customers bring these innovative therapies to market to benefit patients.”
The Dosage Form Solutions President, Amit Patel, added, “Our clients continue to seek innovative and integrated solutions to their formulation challenges. Advancing our inhalation formulation offering to Phase 2-scale GMP supplies – through the use of our specialized equipment, formulation know-how and capsule expertise – represents another way in which Capsugel is collaborating with customers on the development of better medicines for patients.”
Read the Capsugel press release.
